login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
FORTE BIOSCIENCES INC (FBRX) Stock News
USA
-
Nasdaq
- NASDAQ:FBRX -
US34962G2084
-
Common Stock
18.56
USD
-0.52 (-2.73%)
Last: 11/28/2025, 8:27:05 PM
18.55
USD
-0.01 (-0.05%)
After Hours:
11/28/2025, 8:27:05 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
FBRX Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
16 days ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
a month ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
2 months ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
a year ago - By: Benzinga
Why Forte Biosciences (FBRX) Stock Is Trading Lower
3 months ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
4 months ago - By: The Motley Fool
Forte Biosciences Tops Q2 Loss Forecasts
4 months ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Results and Provides Update
5 months ago - By: Benzinga
- Mentions:
NKTR
CCM
ONMD
ANVS
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
a year ago - By: BusinessInsider
FBRX Stock Earnings: Forte Biosciences Misses EPS for Q2 2024
a year ago - By: InvestorPlace
FBRX Stock Earnings: Forte Biosciences Misses EPS for Q2 2024
5 months ago - By: Forte Biosciences, Inc.
Forte Biosciences Announces Pricing of $75 Million Public Offering
5 months ago - By: Forte Biosciences, Inc.
Forte Biosciences Announces Proposed Public Offering
5 months ago - By: Forte Biosciences, Inc.
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
7 months ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Results and Provides Update
8 months ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
10 months ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
a year ago - By: Forte Biosciences, Inc.
Forte Biosciences to Host R&D Day December 3, 2024
a year ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
a year ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
a year ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update
2 years ago - By: Forte Biosciences, Inc.
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Please enable JavaScript to continue using this application.